A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients.

Wim van Boxtel,Maike Uijen,Chantal M. L. Driessen,Sjoert A. H. Pegge,Stefan M. Willems,Marianne A. Jonker,Tim Dijkema,Ilse A. van Engen ‐ van Grunsven,Carla M.L. van Herpen

A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients.

2020

Wim van Boxtel
Maike Uijen
Chantal M. L. Driessen
Sjoert A. H. Pegge
Stefan M. Willems
Marianne A. Jonker
Tim Dijkema
Ilse A. van Engen ‐ van Grunsven
Carla M.L. van Herpen

6529A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients. Background: Because c-MET and VEGFR are often overexpressed in salivary gla...

Keywords:

Oncology
Internal medicine
Pathology
Toxicity
Phases of clinical research
Medicine
Salivary gland cancer
Cabozantinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations